Myriad Genetics (MYGN) Stock Falls on Q4 2025 Earnings

Myriad Genetics Inc. (MYGN) reported fourth-quarter 2025 results.

Revenue: $209.8 million (down 0.4% year over year)

Gross profit: $146.8 million (down 2.7% year over year)

Operating loss: $5.7 million (operating profit fell 85.4% year over year)

Net loss attributable to common shareholders: $7.9 million (down 77.9% year over year)

Diluted earnings per share: -$0.08 (decline of 83.0% year over year)

Results versus expectations:

Revenue came in slightly below forecasts at $209.8 million versus an estimate of $211.5 million.

Reported diluted EPS of -$0.08 missed the estimate of approximately -$0.015.

Cash flow and balance sheet highlights:

Cash provided by operating activities improved to $10.6 million (up 60.6% year over year).

Capital expenditures were $2.8 million (down 22.2% year over year).

Cash and cash equivalents totaled $149.6 million (up 46.1% year over year).

Total liabilities were about $338.6 million (up 3.7% year over year).

Cost of sales totaled $63.0 million (up 5.5% year over year).

Market reaction: shares moved by 11.19% since market close.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Myriad Genetics Inc. Hedge Fund Activity

We have seen 110 institutional investors add shares of Myriad Genetics Inc. stock to their portfolio, and 133 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MILLENNIUM MANAGEMENT LLC added 1,951,831 shares (+41.1%) to their portfolio in Q4 2025, for an estimated $12,003,760
KENT LAKE PR LLC removed 1,250,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $9,037,500
PORTOLAN CAPITAL MANAGEMENT, LLC removed 1,163,400 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $8,411,382
STATE STREET CORP added 990,075 shares (+19.9%) to their portfolio in Q4 2025, for an estimated $6,088,961
DISCIPLINED GROWTH INVESTORS INC /MN removed 753,956 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $5,451,101
VESTAL POINT CAPITAL, LP added 623,000 shares (+103.8%) to their portfolio in Q4 2025, for an estimated $3,831,450
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 579,359 shares (-72.1%) from their portfolio in Q4 2025, for an estimated $3,563,057

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Myriad Genetics Inc. Government Contracts

We have seen $14,994 of award payments to $MYGN over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

PROLARIS PROSTATE CANCER TESTING FOR SLCVAMC ORDERING PERIOD 5: $14,994

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

Myriad Genetics Inc. Analyst Ratings

Wall Street analysts have issued reports on $MYGN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Piper Sandler issued a "Overweight" rating on 11/11/2025

To track analyst ratings and price targets for Myriad Genetics Inc., check out Quiver Quantitative's $MYGN forecast page.

Myriad Genetics Inc. Price Targets

Multiple analysts have issued price targets for $MYGN recently. We have seen 4 analysts offer price targets for $MYGN in the last 6 months, with a median target of $8.25.

Here are some recent targets:

Dave Weiner from Piper Sandler set a target price of $8.5 on 11/11/2025
Brandon Couillard from Wells Fargo set a target price of $6.5 on 11/05/2025
Dan Brennan from TD Cowen set a target price of $9.0 on 11/04/2025
Lu Li from UBS set a target price of $8.0 on 11/04/2025